Cassava shares suffer again after news of SEC probe

18 November 2021

Shareholders in US biotech Cassava Sciences (Nasdaq: SAVA) continue to endure a bumpy ride, with the stock’s value plummeting by 24% on Wednesday.

Shares in Cassava have risen by nearly 600% over the year as a whole but they have zigzagged in recent months amid questions about the firm’s scientific integrity.

"We have been cooperating and will continue to cooperate with government authorities"The stock had recovered somewhat since August’s allegations, filed by a lawyer on behalf of unnamed clients, claiming that some results on the Alzheimer’s candidate simufilam appeared to suggest data manipulation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK